Lek to Launch "Omeprazol" on the U.S. Market
Ljubljana, 19 August - The Ljubljana-based pharmaceutical company Lek, whose majority owner is Swiss Novartis, will launch the anti-heartburn drug omeprazol on the U.S. market this week through its affiliated company Lek Pharmaceuticals. As the company reported on Tuesday, a medicine with the same active ingredient has so far been sold on the U.S. market by the English-Swedish concern Astra Zeneca, under the brand name Prilosec.
The rest of this news item is available to subscribers.
The news item consists of 510 characters (without spaces) or 96 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.